These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 25295493)

  • 41. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
    Loh JP; Stella PR; Sangiorgi G; Silber S; Stahnke S; von Strandmann RP; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2014 Jan; 15(1):23-8. PubMed ID: 24444473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
    Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update.
    Lupi A; Gabrio Secco G; Rognoni A; Lazzero M; Fattori R; Sheiban I; Sante Bongo A; Bolognese L; Agostoni P; Porto I
    Catheter Cardiovasc Interv; 2014 May; 83(6):E193-206. PubMed ID: 24478247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial.
    Tandjung K; Basalus MW; Sen H; Stoel MG; van Houwelingen KG; Louwerenburg JH; de Man FH; Linssen GC; Saïd SA; Kleijne MA; van der Palen J; von Birgelen C
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):396-405. PubMed ID: 23359390
    [TBL] [Abstract][Full Text] [Related]  

  • 47. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology.
    Talarico GP; Burzotta F; Trani C; Tommasino A; Niccoli G; Porto I; Leone AM; Mongiardo R; Schiavoni G; Crea F
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):268-73. PubMed ID: 22639426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: a real-life multicenter experience.
    Buja P; D'Amico G; Facchin M; Barioli A; Napodano M; Capodanno D; Musumeci G; Frigo AC; Saia F; Menozzi A; De Benedictis M; Lee MS; Lettieri C; Tamburino C; Sardella G; Isabella G; Tarantini G
    Int J Cardiol; 2013 Sep; 168(1):139-43. PubMed ID: 23103143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
    Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R
    JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
    Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
    Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents.
    Han Y; Xu B; Jing Q; Lu S; Yang L; Xu K; Li Y; Li J; Guan C; Kirtane AJ; Yang Y;
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1352-60. PubMed ID: 25440887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
    Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
    JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
    Stefanini GG; Byrne RA; Serruys PW; de Waha A; Meier B; Massberg S; Jüni P; Schömig A; Windecker S; Kastrati A
    Eur Heart J; 2012 May; 33(10):1214-22. PubMed ID: 22447805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meeting the Unmet - The Cre8 Polymer-free Drug-eluting Stents Technology: Proceedings of a satellite symposium held at EuroPCR on May 20th - 23rd 2014 in Paris.
    Mountfort K; Carrié D; Valgimigli M; Sardella G; Banai S; Romaguera R; Stella P
    Interv Cardiol; 2014 Aug; 9(3):184-189. PubMed ID: 29588800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent.
    Byrne RA; Eeckhout E; Sardella G; Stella P; Verheye S
    Interv Cardiol; 2017 May; 12(1):13-17. PubMed ID: 29588724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amphilimus-eluting stents in coronary artery disease: finally, a sweet spot for patients with diabetes mellitus?
    Byrne RA; Rai H; Colleran R
    Eur Heart J; 2022 Mar; 43(13):1331-1333. PubMed ID: 35137030
    [No Abstract]   [Full Text] [Related]  

  • 58. Moving Beyond the Stent: Identifying the Percutaneous Coronary Intervention Patient With Silent Diabetes and Pre-Diabetes.
    Farkouh ME
    JACC Cardiovasc Interv; 2018 Mar; 11(5):460-461. PubMed ID: 29454729
    [No Abstract]   [Full Text] [Related]  

  • 59. The Challenge of Diabetes Mellitus in the Contemporary Percutaneous Coronary Intervention Era: Are We Making Progress?
    Baber U
    JACC Cardiovasc Interv; 2018 Dec; 11(24):2477-2479. PubMed ID: 30573058
    [No Abstract]   [Full Text] [Related]  

  • 60. Labeling Stents/Scaffolds for Diabetes: Real Science or Marketing Stunt?
    Waksman R
    JACC Cardiovasc Interv; 2017 Jan; 10(1):50-52. PubMed ID: 28017312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.